Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide

<div>Comparative survival outcomes between the pan-immune-inflammation value (PIV) groups. (a) Progression-free survival. (b) Overall survival (dark blue: low pan-immune-inflammation value; red: high pan-immune-inflammation value).</div>

Journal of Immunology Research

fig2

Figure 2

Figure 2: Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide 

Figure 2 | Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide 